Polish standard of treatment with racemic ketamine for patients with depressive disorders developed by a Working Group appointed by the National Consultant in the field of psychiatry.
Psychiatria polska June 30, 2024 Piotr Gałecki, Katarzyna Maria Bliźniewska-Kowalska, Wiesław Jerzy Cubała et al. 5 citations
A Polish expert panel developed national treatment standards for intravenous racemic ketamine in depressive disorders, addressing the one-third of depressed patients who do not respond to standard antidepressants. The guidelines summarize research on ketamine's efficacy and safety for unipolar and bipolar depression, leveraging its action as an NMDA receptor antagonist to modulate the overactive glutamatergic system implicated in depression. The recommendations cover indications, contraindications, precautions, and treatment protocols, aiming to expand therapeutic options for practicing psychiatrists.